Sharing Responses to Public Consultations

Sharing Responses to Public Consultations

PDCI voluntarily hosts this webpage as an information sharing platform for recent public consultations concerning pharmaceutical policy issues. PDCI invites ALL stakeholders who have participated in any of the below-listed public consultations to publicly share their written comments with other stakeholders via this PDCI webpage. Our objective for this record of responses on Government consultations is to support transparency in policy-making. We wish to ensure public dialogue and information-sharing is as comprehensive as possible and includes all voices that will inform forthcoming policy decisions on consultation topics.

If you or your organization responded to any of the below-listed public consultations and would like to share your response with the public, please contact PDCI’s Managing Director, Kaitlyn Proulx at Kaitlyn.Proulx@pdci.ca or (613) 742-8225 ext. 33. Please attach PDF version(s) of your English and/or French submissions and indicate your permission for PDCI to share your submission on on this webpage. If your submission contains confidential or proprietary information but you are still wish to share your comments, you may send a PDF copy with confidential information redacted, or you can be added to the list of “Other Stakeholders who Shared Confidential Comments”.

National Pharmacare Consultations – Summer 2018

National Pharmacare Consultations – Summer 2018

Announced in the 2018 federal budget and chaired by former Ontario Health Minister Eric Hoskins, the Advisory Council on the Implementation of National Pharmacare is currently engaging in a national dialogue on how the federal government could implement affordable national pharmacare for Canadians. As part of this dialogue, the Council is seeking written responses to its discussion paper Towards Implementation of National Pharmacare, including questions around who should be covered, what drugs should be covered and who should pay for the coverage. Written consultation comments are due by September 28, 2018.

Input received from this and the Council’s other ongoing consultation activities will inform the Council’s report to the federal ministers of health and finance in Spring 2019.

Below are stakeholder responses to this consultation which have been voluntarily shared by their authors for posting on this landing page. Please email your submission to Kaitlyn.Proulx@pdci.ca if you would like your voice added to this page.

Canada Gazette Part I Consultation Responses – February 2018

Canada Gazette Part I Consultation Responses – February 2018

The process to amend the Patented Medicines Regulations is well underway in Canada. These amendments are anticipated to significantly change the way patented medicine prices are regulated in Canada. As part of the process, Health Canada has held two consultations seeking stakeholder feedback on its proposed amendments.

In December 2017, the Governor-in-Council published Health Canada’s proposed changes to the Patented Medicines Regulations in Canada Gazette Part 1. Stakeholder comments were invited on the Regulatory Impact Analysis Statement (RIAS) and proposed regulatory text, with the consultation period ending February 14, 2018.  Below are stakeholder responses to that consultation which have been voluntarily shared for posting on this landing page.

Please email your submission to Kaitlyn.Proulx@pdci.ca if you would like your voice added to this page.

  • Best Medicines Coalition
    • Alliance for Access to Psychiatric Medications
    • Arthritis Consumer Experts
    • Asthma Canada
    • Better Pharmacare Coalition
    • Brain Tumour Foundation of Canada
    • Canadian Arthritis Patient Alliance
    • Canadian Breast Cancer Network
    • Canadian Council of the Blind
    • Canadian Epilepsy Alliance
    • Canadian Hemophilia Society
    • Canadian PKU & Allied Disorders
    • Canadian Psoriasis Network
    • Canadian Skin Patient Alliance
    • Canadian Society of Intestinal Research
    • Canadian Spondylitis Association
    • Canadian Treatment Action Council
    • Crohn’s and Colitis Canada
    • Foundation Fighting Blindness
    • Gastrointestinal Society
    • Health Coalition of Alberta
    • Kidney Cancer Canada
    • Lymphoma Canada
    • Ovarian Cancer Canada
    • Parkinson Canada
  • Draft prepared and coordinated by Myeloma Canada and Save Your Skin Foundation and endorsed by 28 Patient Organizations:
    • Canadian Arthritis Patient Alliance (CAPA)
    • Canadian Cancer Survivor Network (CCSN)
    • Canadian MPN Network
    • Canadian Obesity Network
    • Canadian Psoriasis Network
    • Canadian Skin Patient Alliance (CSPA)
    • Canadian Spondylitis Association (CSA)
    • Canadian Treatment Action Council (CTAC)
    • Carcinoid-NeuroEndocrine Tumour Society of Canada (CNETS)
    • Cardiac Health Foundation of Canada
    • Centre Associatif Polyvalent d’Aide Hépatite C (CAPAHC)
    • Collective Oncology Network for Exchange, Cancer Care Innovation, Treatment Access and Education (CONECTed)
    • Colorectal Cancer Canada
    • Life-Saving Therapies Network
    • Lung Cancer Canada
    • Lymphoma Canada
    • Melanoma Network of Canada
    • Myeloma Canada
    • Pancreatic Cancer Canada
    • Save Your Skin Foundation (SYSF)
    • Schizophrenia Society of Ontari(SSO)
    • Sickle Cell Awareness Group of Ontari(SCAGO)
    • Team Finn Foundation
    • The Canadian CML Network
    • The Chronic Myelogenous Leukemia (CML) Society of Canada
    • The Lung Association – Ontario

Other Stakeholders that Shared Confidential Comments with Health Canada

  • Servier Canada inc.

Proposed Amendments to The Patented Medicines Regulations – June 2017

Proposed Amendments to The Patented Medicines Regulations Consultation Responses – June 2017

The process to amend the Patented Medicines Regulations is well underway in Canada. These amendments are anticipated to significantly change the way patented medicine prices are regulated in Canada. As part of the process, Health Canada has held two consultations seeking stakeholder feedback on its proposed amendments.

In May 2017, the Federal Minister of Health launched a consultation on proposed amendments to the Patented Medicines Regulations that would have significant effects on how patented drug prices are regulated in Canada. The consultation period closed June 28, 2017. Below are stakeholder responses to that consultation which have been voluntarily shared for posting on this landing page.

  • Draft prepared and coordinated by Myeloma Canada and Save Your Skin Foundation and endorsed by 18 Patient Organizations:

    • Canadian Cancer Survivor Network (CCSN)
    • Canadian Psoriasis Network
    • Canadian Spondylitis Association
    • Carcinoid-NeuroEndocrine Tumor Society (CNETs)
    • Collective Oncology Network for Exchange, Innovation in Cancer Care, Treatment Access and Education (CONECTed)
    • Hep C BC
    • Lifesaving Therapies Network
    • Lung Cancer Canada
    • Lymphoma Canada
    • Melanoma Network of Canada
    • Myeloma Canada
    • Ontario Caregiver Coalition
    • Rethink Breast Cancer
    • Save Your Skin Foundation
    • Schizophrenia Society of Ontario (SSO)
    • Sickle Cell Awareness Group of Ontario (SCAGO)
    • Sickle Cell Disease Association of Canada (SCDAC)
    • The Lung Association Ontario

Please be advised:

  • The views and opinions expressed in the consultation submissions on this page are solely those of the author and DO NOT represent those of PDCI Market Access.
  • This page is intended to be a repository of submissions for the purpose of transparency and information sharing. It is not intended to promote or lobby on behalf of any specific stakeholder, individual, group or interest.
  • PDCI has accepted no funds whatsoever to support this initiative.
  • PDCI is welcoming submissions from ALL individuals, stakeholders, groups, etc. who made submissions as part of these public consultations, however this repository is not comprehensive. PDCI makes efforts to reach all stakeholder communities who may have submitted to make them aware of this repository and to provide information on how to be included, if desired. PDCI will continue to post new submissions as they are received.
  • PDCI is unable to verify the identity of stakeholders who made submissions, nor the content of those submissions. In hosting this website, PDCI therefore assumes that those who have provided PDCI their submissions for inclusion in this repository have done so in good faith and have provided PDCI with the submission identical to that which they provided to Health Canada for purposes of the consultation.
  • To the best of PDCI’s knowledge, all submissions have been prepared independently and/or authors of submissions have appropriately disclosed any conflicts of interest within their submissions.
  • PDCI cannot be held responsible for the content of any submissions including but not limited to any inaccurate information.